Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder. We have found that salidroside (Sal) exhibited neuroprotective effects against MPP+ toxicity. However, the molecular mechanism is not fully understood. In this study, we found that Sal significantly prevented MPP+-induced decrease of mRNA and protein expression of Nrf2, GCLc, SOD1, and SOD2 in SH-SY5Y cells. Moreover, silencing of Nrf2 significantly inhibited Sal-induced increase in mRNA and protein expression of GCLc, SOD1, and SOD2. But Nrf2 silence did not significantly impact Sal-exhibited effects on DJ-1 expression. Silencing of Nrf2 significantly suppressed the decrease of apoptosis induced by Sal in MPP+-treated SH-SY5Y cells. Sal significantly prevented MPP+-induced decrease of the mRNA and protein expression of DJ-1 in SH-SY5Y cells. Moreover, silencing of DJ-1 significantly inhibited Sal-induced increase in mRNA and protein expression of Nrf2, GCLc, SOD1, and SOD2 in MPP+-treated SH-SY5Y cells. These results indicated that DJ-1 was an upstream regulator of Nrf2 in the neuroprotective effects of Sal. Furthermore, silencing of DJ-1 significantly suppressed the decrease of apoptosis induced by Sal in MPP+-treated SH-SY5Y cells. In conclusion, Sal prevented MPP+-induced neurotoxicity through upregulation of DJ-1-Nrf2-antioxidant pathway. Our findings provide novel insights into the neuroprotective effects of Sal against PD.

Highlights

  • Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting more than 1% of humans over 60 years of age [1, 2]

  • We evaluated the neuroprotective effect of Salidroside (p-hydroxyphenethyl-b-D-glucoside; C14H20O7) (Sal) using SH-SY5Y cells

  • We found that Sal significantly decreased the number of Annexin V/propidium iodide (PI)-stained cells treated by MPP+ which was in a concentration-dependent manner (Figure 2(a))

Read more

Summary

Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting more than 1% of humans over 60 years of age [1, 2]. Clinical therapy of PD is limited by shortage of validated drugs [7, 8].

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call